<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="gsd5" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">gsd5</book-part-id>
      <title-group>
        <title>Glycogen Storage Disease Type V</title>
        <alt-title alt-title-type="alt-title">Synonyms: Glycogenosis Type V, GSDV, McArdle Disease, Muscle Glycogen Phosphorylase Deficiency, Myophosphorylase Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Mart&#x000ed;n</surname>
            <given-names>Miguel A</given-names>
          </name>
          <xref ref-type="aff" rid="gsd5.AFF1"/>
          <degrees>PhD</degrees>
          <email>mamcasanueva@h12o.es</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Luc&#x000ed;a</surname>
            <given-names>Alejandro</given-names>
          </name>
          <xref ref-type="aff" rid="gsd5.AFF2"/>
          <degrees>MD, PhD</degrees>
          <email>alejandro.lucia@uem.es</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Arenas</surname>
            <given-names>Joaquin</given-names>
          </name>
          <xref ref-type="aff" rid="gsd5.AFF3"/>
          <degrees>PhD</degrees>
          <email>joaquin.arenas@salud.madrid.org</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Andreu</surname>
            <given-names>Antonio L</given-names>
          </name>
          <xref ref-type="aff" rid="gsd5.AFF4"/>
          <degrees>MD, PhD</degrees>
          <email>toniandreu.bcn@gmail.com</email>
        </contrib>
      </contrib-group>
      <aff id="gsd5.AFF1">Hospital 12 de Octubre Research Institute (i+12) and<break/>Center for Biomedical Research in Rare Diseases Network (CIBERER)<break/>Madrid, Spain </aff>
      <aff id="gsd5.AFF2">European University of Madrid (UEM) and<break/>Hospital 12 de Octubre Research Institute (i+12)<break/>Madrid, Spain</aff>
      <aff id="gsd5.AFF3">Hospital 12 de Octubre Research Institute (i+12)<break/>Madrid, Spain</aff>
      <aff id="gsd5.AFF4">Hospital Universitari Vall d&#x02019;Hebron Institut de Recerca (VHIR)<break/>Barcelona, Spain</aff>
      <pub-history>
        <date iso-8601-date="2006-04-19" date-type="created">
          <day>19</day>
          <month>04</month>
          <year>2006</year>
        </date>
        <date iso-8601-date="2014-06-26" date-type="updated">
          <day>26</day>
          <month>06</month>
          <year>2014</year>
        </date>
        <date iso-8601-date="2006-05-08" date-type="revised">
          <day>08</day>
          <month>05</month>
          <year>2006</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="gsd4" document-type="chapter">Glycogen Storage Disease Type IV</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="gsd6" document-type="chapter">Glycogen Storage Disease Type VI</related-object>
      <abstract id="gsd5.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Glycogen storage disease type V (GSDV, McArdle disease) is a metabolic myopathy characterized by exercise intolerance manifested by rapid fatigue, myalgia, and cramps in exercising muscles. Symptoms usually are precipitated by isometric exercise or sustained aerobic exercise. Most individuals improve their exercise tolerance by exploiting the "second wind" phenomenon with relief of myalgia and fatigue after a few minutes of rest. Age of onset is frequently in the first decade of life but can vary. Fixed muscle weakness occurs in approximately 25% of affected individuals, is more likely to involve proximal muscles, and is more common in individuals of advanced age. Approximately 50% of affected individuals have recurrent episodes of myoglobinuria that could eventually result in acute renal failure, although reported cases are rare.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>GSDV is diagnosed by clinical findings, supportive laboratory findings (i.e., increased resting serum creatine kinase [CK] activity and no change in plasma lactate concentration on the forearm non-ischemic or ischemic test), and the cycle test (a specific, sensitive, and simple test that is based on the pathognomonic heart rate response observed in the second wind phenomenon). The diagnosis is confirmed by molecular genetic testing of <italic toggle="yes">PYGM</italic> (encoding glycogen phosphorylase, muscle form), the only gene known to be associated with GSDV. Targeted mutation analysis identifies the most common pathogenic variants, p.Arg50Ter and p.Gly205Ser. Assay of myophosphorylase enzyme activity confirms the diagnosis when genetic diagnosis is unclear. </p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Although no cure for GSDV is available, affected individuals benefit from moderate-intensity aerobic training (e.g., walking or brisk walking, bicycling) to increase cardiorespiratory fitness and muscle oxidative capacity. Pre-exercise ingestion of sports drinks containing simple carbohydrates improves exercise tolerance and may protect against exercise-induced rhabdomyolysis. </p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Caution with general anesthesia because it may cause acute muscle damage. </p>
          <p><italic toggle="yes">Surveillance</italic>: Annual routine physical examination and review of diet. </p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> To prevent occurrence of cramps and myoglobinuria, avoid intense isometric exercise and maximal aerobic exercise. </p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> When the family-specific pathogenic variants are known, early detection of GSDV in relatives at risk ensures proper management to prevent muscle injury leading to rhabdomyolysis and to improve long-term outcome &#x02013; particularly by adoption of a healthy lifestyle (i.e., regular exercise practice such as brisk walking) in childhood. </p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>GSDV is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier. Once an at-risk sib is known to be unaffected, the risk of being a carrier is 2/3. Heterozygotes are asymptomatic. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants have been identified in the family.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="gsd5.Diagnosis">
        <title>Diagnosis</title>
        <sec id="gsd5.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Glycogen storage disease type V (GSDV) is suspected in individuals with the following supportive clinical and laboratory findings.</p>
          <p>Clinical findings:</p>
          <list list-type="bullet">
            <list-item>
              <p>Exercise-induced muscle cramps and pain, especially during the first ~10 minutes, that improve after a brief rest period or when exercise intensity is reduced (i.e., the so-called &#x02018;second wind phenomenon&#x02019;). </p>
            </list-item>
            <list-item>
              <p>Episodes of myoglobinuria</p>
            </list-item>
          </list>
          <p>Laboratory findings: </p>
          <list list-type="bullet">
            <list-item>
              <p>Increased resting serum creatine kinase [CK] activity. A wide range of persistently elevated activities are seen, with mean values frequently exceeding 1,000 IU/L (normal reference values: &#x0003c;200 IU/L).</p>
            </list-item>
            <list-item>
              <p>No change in plasma lactate concentration on the forearm non-ischemic test, which relies on determination of plasma lactate and ammonia concentrations at baseline and within the first two minutes following exercise consisting of repeated maximal one-second handgrips every other second for one minute (~30 contractions). Diagnostic changes in plasma lactate and ammonia concentrations always occur within the first two minutes after exercise [<xref ref-type="bibr" rid="gsd5.REF.kazemiesfarjani.2002.153">Kazemi-Esfarjani et al 2002</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p>In controls: plasma lactate concentrations increase five to six times above basal values.</p>
                </list-item>
                <list-item>
                  <p>In individuals with GSDV: plasma lactate concentration does not increase (the so-called "flat lactate curve") and post-exercise lactate-to-ammonia peak ratios are clearly decreased.Note: (1) Persons with a glycogen storage disease have exaggerated responses of plasma ammonia concentration to exercise; therefore, measuring plasma ammonia concentration is as informative as measuring plasma lactate concentration. (2) The non-ischemic lactate forearm test [<xref ref-type="bibr" rid="gsd5.REF.kazemiesfarjani.2002.153">Kazemi-Esfarjani et al 2002</xref>] has the same diagnostic power as the ischemic lactate forearm test but eliminates the cramps, pain, and potential muscle injury produced by the ischemic test. (3) The ischemic lactate forearm test is no longer used. Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="PDF File" xlink:href="gsd5-ischemic-test.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for more information. </p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Cycle and walking test.</bold> A cycle test is a physiologic test in which only heart rate needs to be monitored to detect the pathognomonic heart rate response of the second wind phenomenon, manifest by all individuals with GSDV (i.e., marked increase in heart rate [&#x0003e;+30-40 beats/min] during the first ~10 minutes of a cycle test at moderate intensity [~40 watts for adults] together with frequent symptoms of myalgia and cramps, followed by a decrease in heart rate and muscle symptoms [<xref ref-type="bibr" rid="gsd5.REF.vissing.2003a.539">Vissing &#x00026; Haller 2003a</xref>]). This test provides a sensitive, specific, and simple diagnostic test for GSDV with no possibility of false positive results. A walking test can also be performed in less specialized clinical settings to detect the second wind in persons with GSDV [<xref ref-type="bibr" rid="gsd5.REF.buckley.2014.1">Buckley et al 2014</xref>].</p>
        </sec>
        <sec id="gsd5.Confirming_the_Diagnosis">
          <title>Confirming the Diagnosis</title>
          <p>The diagnosis of GSDV is confirmed in a proband by identification of biallelic pathogenic variants in <italic toggle="yes">PYGM</italic> on <bold>molecular genetic testing</bold> or &#x02013; if genetic testing results are unclear &#x02013; by <bold>assay of muscle myophosphorylase enzyme activity</bold> with biochemical or histochemical methods.</p>
          <p><bold>Molecular genetic testing</bold> of <italic toggle="yes">PYGM</italic>, encoding myophosphorylase (glycogen phosphorylase, muscle form) (<xref ref-type="table" rid="gsd5.T.summary_of_molecular_genetic_test">Table 1</xref>):</p>
          <list list-type="bullet">
            <list-item>
              <p>A molecular genetic testing strategy in some specific populations (e.g., Spaniards) involving use of a diagnostic flowchart has been proposed: sequential testing for the three common pathogenic variants in this population (<xref ref-type="table" rid="gsd5.T.summary_of_molecular_genetic_test">Table 1</xref> and <xref ref-type="table" rid="gsd5.T.pygm_pathogenic_variants_other_th">Table 4</xref>), followed by sequence analysis of several <italic toggle="yes">PYGM</italic> hot-spot exons (i.e., 1, 14, 17, and 18) [<xref ref-type="bibr" rid="gsd5.REF.martin.2001.574">Mart&#x000ed;n et al 2001</xref>, <xref ref-type="bibr" rid="gsd5.REF.rubio.2007a.203">Rubio et al 2007a</xref>].</p>
            </list-item>
            <list-item>
              <p>Another molecular genetic testing strategy is sequence analysis of <italic toggle="yes">PYGM,</italic> followed by deletion/duplication analysis in those very rare instances in which no or only one pathogenic variant is found [<xref ref-type="bibr" rid="gsd5.REF.garciaconsuegra.2009.198">Garc&#x000ed;a-Consuegra et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p>Yet another molecular genetic testing strategy is use of a multi-gene panel that includes <italic toggle="yes">PYGM</italic> and other genes of interest (see <xref ref-type="sec" rid="gsd5.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time. </p>
            </list-item>
          </list>
          <table-wrap id="gsd5.T.summary_of_molecular_genetic_test" position="anchor" orientation="portrait">
            <label>Table 1.</label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Glycogen Storage Disease Type V</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_2" colspan="2" align="left" valign="middle" rowspan="1">Test Method</th>
                  <th id="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_1" align="left" valign="middle" rowspan="4" colspan="1">
                    <italic toggle="yes">PYGM</italic>
                  </td>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_2" align="left" valign="middle" rowspan="2" colspan="1">Targeted mutation analysis </td>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">p.Arg50Ter&#x000a0;<sup>2,</sup>&#x000a0;<sup>3</sup></td>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">32%-85%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">p.Gly205Ser <sup>5</sup></td>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">9%-10%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_2" colspan="2" align="left" valign="middle" rowspan="1">Sequence analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">97%-100%&#x000a0;<sup>7</sup></td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_2" colspan="2" align="left" valign="middle" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>8</sup></td>
                  <td headers="hd_b_gsd5.T.summary_of_molecular_genetic_test_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1%&#x000a0;<sup>9</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gsd5.TF.1">
                <label>1.</label>
                <p>See <related-object source-id="gene" document-id="gsd5" object-id="gsd5.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="gsd5.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants. </p>
              </fn>
              <fn id="gsd5.TF.1.1">
                <label>2.</label>
                <p><xref ref-type="table" rid="gsd5.T.pygm_pathogenic_variants_other_th">p.Arg50Ter</xref>, a nonsense mutation at codon 50 in exon 1, is the most common pathogenic variant causing GSDV among individuals of European and US descent [<xref ref-type="bibr" rid="gsd5.REF.andreu.1998.260">Andreu et al 1998</xref>, <xref ref-type="bibr" rid="gsd5.REF.martin.2001.574">Mart&#x000ed;n et al 2001</xref>, <xref ref-type="bibr" rid="gsd5.REF.bruno.2006.718">Bruno et al 2006</xref>, <xref ref-type="bibr" rid="gsd5.REF.aquaron.2007.235">Aquaron et al 2007</xref>, <xref ref-type="bibr" rid="gsd5.REF.deschauer.2007.797">Deschauer et al 2007</xref>, <xref ref-type="bibr" rid="gsd5.REF.rubio.2007a.203">Rubio et al 2007a</xref>, <xref ref-type="bibr" rid="gsd5.REF.lucia.2012.322">Lucia et al 2012</xref>]. p.Arg50Ter has never been found in individuals of Japanese descent.</p>
              </fn>
              <fn id="gsd5.TF.1.2">
                <label>3.</label>
                <p>p.Lys543Thr is included in some panels but is not commonly seen in individuals with GSDV.</p>
              </fn>
              <fn id="gsd5.TF.1.3">
                <label>4.</label>
                <p>Percentages taken from <xref ref-type="bibr" rid="gsd5.REF.bartram.1993.1291">Bartram et al [1993]</xref>, <xref ref-type="bibr" rid="gsd5.REF.tsujino.1993.241">Tsujino et al [1993]</xref>, <xref ref-type="bibr" rid="gsd5.REF.elschahawi.1996.579">el-Schahawi et al [1996]</xref>, <xref ref-type="bibr" rid="gsd5.REF.andreu.1998.260">Andreu et al [1998]</xref>, <xref ref-type="bibr" rid="gsd5.REF.martin.2001.574">Mart&#x000ed;n et al [2001]</xref>, <xref ref-type="bibr" rid="gsd5.REF.bruno.2006.718">Bruno et al [2006]</xref>, <xref ref-type="bibr" rid="gsd5.REF.aquaron.2007.235">Aquaron et al [2007]</xref>, <xref ref-type="bibr" rid="gsd5.REF.deschauer.2007.797">Deschauer et al [2007]</xref>, <xref ref-type="bibr" rid="gsd5.REF.rubio.2007a.203">Rubio et al [2007a]</xref>
</p>
              </fn>
              <fn id="gsd5.TF.1.4">
                <label>5.</label>
                <p><xref ref-type="table" rid="gsd5.T.pygm_pathogenic_variants_other_th">p.Gly205Ser</xref> is the second most common pathogenic variant, accounting for approximately 9% of mutant alleles in various European and US populations.</p>
              </fn>
              <fn id="gsd5.TF.1.5">
                <label>6.</label>
                <p>Sequence analysis detects all the common variants discussed above as well as other variants that are benign, likely benign, of unknown significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="gsd5.TF.1.6">
                <label>7.</label>
                <p>
                  <xref ref-type="bibr" rid="gsd5.REF.kubisch.1998.27">Kubisch et al [1998]</xref>
                </p>
              </fn>
              <fn id="gsd5.TF.1.7">
                <label>8.</label>
                <p>Testing that identifies exonic or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment. </p>
              </fn>
              <fn id="gsd5.TF.1.8">
                <label>9.</label>
                <p>Large deletions of <italic toggle="yes">PYGM</italic> are very rare; a 1094 bp deletion, c.1969+214_2177+369del, extending from intron 16 to intron 17 has been reported [<xref ref-type="bibr" rid="gsd5.REF.garciaconsuegra.2009.198">Garc&#x000ed;a-Consuegra et al 2009</xref>]. </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Myophosphorylase enzyme activity.</bold> Myophosphorylase E.C. 2.4.1.1 is the muscle isoenzyme of glycogen phosphorylase. Qualitative histochemistry or quantitative biochemical analysis in a muscle biopsy or muscle homogenate is diagnostic. In persons with GSDV the residual activity of myophosphorylase in GSDV is virtually undetectable. </p>
        </sec>
      </sec>
      <sec id="gsd5.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="gsd5.Natural_History">
          <title>Clinical Description</title>
          <p>Glycogen storage disease type V (GSDV) is a metabolic myopathy with onset frequently in the first decade of life. Clinical heterogeneity exists; some individuals have mild symptoms manifesting as fatigue or poor stamina without cramps, whereas a severe, rapidly progressive form manifests shortly after birth. In some individuals, progressive weakness manifests in the sixth or seventh decade of life [<xref ref-type="bibr" rid="gsd5.REF.wolfe.2000.641">Wolfe et al 2000</xref>]. The fixed weakness that occurs in approximately one fourth of affected individuals is more likely to involve proximal muscles and is more common in individuals over age 40 years. Most individuals learn to adjust their daily activities and can have relatively normal lives.</p>
          <p>The usual presentation of GSDV is exercise intolerance, including stiffness or weakness of the muscles being used, myalgia, and fatigue in the first few minutes of exercise. These symptoms are usually precipitated by isometric exercise (e.g., carrying weights) and sustained vigorous aerobic exercise (e.g., stair-climbing, jogging), and typically are relieved by rest. Any skeletal muscle can be affected. </p>
          <p>Many individuals remember painful symptoms from early childhood, but the disorder is rarely diagnosed before adulthood. Some people notice a worsening of their symptoms in middle age that may be accompanied by some muscle wasting. Presentation with exertional dyspnea has been described [<xref ref-type="bibr" rid="gsd5.REF.voduc.2004.163">Voduc et al 2004</xref>].</p>
          <p>Most individuals learn to improve their exercise tolerance by exploiting the "second wind" phenomenon, a unique feature of GSDV, that is, relief of myalgia and rapid fatigue after a few minutes of rest. The metabolic events underlying the second wind are the increased supply of blood-borne glucose and free fatty acids as exercise progresses, leading to a switch in metabolic pathways from endogenous glycolysis to oxidative phosphorylation of blood-borne fatty acids [<xref ref-type="bibr" rid="gsd5.REF.haller.2002.1395">Haller &#x00026; Vissing 2002</xref>]. The ability to develop a second wind is greatly increased in those who keep physically fit through aerobic exercise, such as walking. In contrast, sustained or strenuous exercise, such as lifting heavy weights or sprinting, carries a high risk of muscle damage. Continuing to exercise in the presence of severe pain also results in muscle damage (rhabdomyolysis) and myoglobinuria, with the attending risk of acute renal failure.</p>
          <p>Myoglobinuria occurs in approximately 50% of individuals following intense exercise; however, very few develop acute renal failure. Kidney failure is almost always reversible, but emergency treatment is required [<xref ref-type="bibr" rid="gsd5.REF.lucia.2012.322">Lucia et al 2012</xref>].</p>
          <p>Other presentations of GSDV:</p>
          <list list-type="bullet">
            <list-item>
              <p>Severe paraspinal wasting and weakness [<xref ref-type="bibr" rid="gsd5.REF.witting.2014.88">Witting et al 2014</xref>]</p>
            </list-item>
            <list-item>
              <p>Incidental finding of severe obstructive hypertrophic cardiomyopathy [<xref ref-type="bibr" rid="gsd5.REF.moustafa.2013.769">Moustafa et al 2013</xref>]</p>
            </list-item>
            <list-item>
              <p>Acute renal failure in the absence of exertion [<xref ref-type="bibr" rid="gsd5.REF.walker.2003.640">Walker et al 2003</xref>, <xref ref-type="bibr" rid="gsd5.REF.sidhu.2005.U1614">Sidhu &#x00026; Thompson 2005</xref>]</p>
            </list-item>
            <list-item>
              <p>Hyper-CK-emia (asymptomatic elevations of serum CK activity) up to 17,000 IU/L in the infantile myopathy [<xref ref-type="bibr" rid="gsd5.REF.ito.2003.438">Ito et al 2003</xref>]. Hyper-CK-emia has been reported in adolescents [<xref ref-type="bibr" rid="gsd5.REF.gospe.1998.1228">Gospe et al 1998</xref>, <xref ref-type="bibr" rid="gsd5.REF.bruno.2000.137">Bruno et al 2000</xref>].</p>
            </list-item>
            <list-item>
              <p>Clumsiness, lethargy, and slow movement; observed in eight pre-adolescents [<xref ref-type="bibr" rid="gsd5.REF.roubertie.1998.269">Roubertie et al 1998</xref>]</p>
            </list-item>
          </list>
          <p><bold>Pathophysiology.</bold> The two types of exercise:</p>
          <list list-type="bullet">
            <list-item>
              <p>Aerobic exercise includes walking, gentle swimming, jogging, and cycling. During aerobic exercise, the fuel used by skeletal muscle depends on several factors including: type, intensity, and duration of exercise; physical condition; and dietary regimen. Because aerobic exercise favors the utilization of blood-borne substrates, such as fatty acids, it is better tolerated by individuals with GSDV and thus beneficial as a therapeutic regimen.</p>
            </list-item>
            <list-item>
              <p>Anaerobic exercise is intense but cannot be sustained (e.g., weight lifting or 100-meter dash). Normally, during anaerobic exercise, myophosphorylase converts glycogen to glucose, which enters the glycolytic pathway and produces ATP anaerobically.</p>
            </list-item>
          </list>
          <p>The first few minutes of any exercise have an anaerobic component. Depending on intensity and duration of the exercise, muscle uses different fuel sources such as anaerobic glycolysis, blood glucose, muscle glycogen, and aerobic glycolysis, followed by fatty acid oxidation.</p>
          <p><bold>At rest</bold> the main energy source is blood free fatty acids. These molecules are oxidized in the mitochondrial beta-oxidation pathway to produce acetyl-CoA, which is further metabolized through the Krebs cycle and the mitochondrial respiratory chain resulting in ATP production.</p>
        </sec>
        <sec id="gsd5.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Several studies in European populations did not observe any apparent correlation between severity of clinical findings and genotype [<xref ref-type="bibr" rid="gsd5.REF.martin.2001.574">Mart&#x000ed;n et al 2001</xref>, <xref ref-type="bibr" rid="gsd5.REF.bruno.2006.718">Bruno et al 2006</xref>, <xref ref-type="bibr" rid="gsd5.REF.aquaron.2007.235">Aquaron et al 2007</xref>, <xref ref-type="bibr" rid="gsd5.REF.deschauer.2007.797">Deschauer et al 2007</xref>, <xref ref-type="bibr" rid="gsd5.REF.vieitez.2011.817">Vieitez et al 2011</xref>].</p>
          <p>One study showed that an insertion/deletion (I/D) benign variant in <italic toggle="yes">ACE</italic> (encoding angiotensin converting enzyme), involving the insertion (allele I) or deletion (allele D) situated approximately 250 bp into intron 16 of <italic toggle="yes">ACE</italic>, could play a significant role as a phenotype modulator in individuals with GSDV [<xref ref-type="bibr" rid="gsd5.REF.martinuzzi.2003.497">Martinuzzi et al 2003</xref>]. The <italic toggle="yes">ACE</italic> I allele has been associated with a higher functional capacity in affected females [<xref ref-type="bibr" rid="gsd5.REF.gomezgallego.2008.134">G&#x000f3;mez-Gallego et al 2008</xref>]. </p>
          <p>In the study of 99 individuals with GSDV that assessed the possible effect of several genotype modulators (<italic toggle="yes">ACE</italic>-I/D, <italic toggle="yes">AMPD1</italic>: p.Gln12Ter; <italic toggle="yes">PPARGC1A</italic>: p.Gly482Ser; <italic toggle="yes">ACTN3</italic>: p.Arg577Ter) on clinical severity, no significant relationships were detected except for the <italic toggle="yes">ACE</italic> D allele and the disease severity score described by <xref ref-type="bibr" rid="gsd5.REF.martinuzzi.2003.497">Martinuzzi et al [2003]</xref> and <xref ref-type="bibr" rid="gsd5.REF.rubio.2007b.217">Rubio et al [2007b]</xref>.</p>
        </sec>
        <sec id="gsd5.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of GSDV in the Dallas-Fort Worth, Texas area was estimated at 1:100,000 [<xref ref-type="bibr" rid="gsd5.REF.haller.2000.923">Haller 2000</xref>]. </p>
          <p>The Spanish McArdle Disease patient registry reported a minimum prevalence in that country of nearly 1:170,000 [<xref ref-type="bibr" rid="gsd5.REF.lucia.2012.322">Lucia et al 2012</xref>].</p>
        </sec>
      </sec>
      <sec id="gsd5.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>An extremely rare instance of infantile sudden infant death syndrome (SIDS) in a family with myophosphorylase deficiency has been associated with the common <italic toggle="yes">PYGM</italic> pathogenic variant <xref ref-type="table" rid="gsd5.T.pygm_pathogenic_variants_other_th">p.Arg50Ter</xref> [<xref ref-type="bibr" rid="gsd5.REF.elschahawi.1997.81">el-Schahawi et al 1997</xref>]. </p>
      </sec>
      <sec id="gsd5.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of glycogen storage disease type V (GSDV) includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mitochondrial myopathy (See <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial Disorders Overview</related-object>.)</p>
          </list-item>
          <list-item>
            <p>Myodenylate deaminase deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615511">615511</ext-link>) </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="cpt2" document-type="chapter">Carnitine palmitoyl transferase II deficiency</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Phosphoglycerate kinase 1 deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/300653">300653</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Glycogen storage disease X (phosphoglycerate mutase deficiency) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/261670">261670</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Glycogen storage disease VII (phosphofructokinase deficiency) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/232800">232800</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Glycogen storage disease XI (lactate dehydrogenase deficiency) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/612933">612933</ext-link>)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="gsd9" document-type="chapter">Phosphorylase b kinase deficiency</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Creatine phosphokinase, elevated serum (idiopathic hyper-CK-emia) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/123320">123320</ext-link>)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="vlcad" document-type="chapter">Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Mitochondrial trifunctional protein (MTP) deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/609015">609015</ext-link>)</p>
          </list-item>
        </list>
      </sec>
      <sec id="gsd5.Management">
        <title>Management</title>
        <sec id="gsd5.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with glycogen storage disease type V (GSDV), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Physical examination with emphasis on muscle strength/weakness</p>
            </list-item>
            <list-item>
              <p>Basal serum CK activity</p>
            </list-item>
          </list>
        </sec>
        <sec id="gsd5.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Aerobic training</bold> (on a regular diet). In some individuals, improvement in exercise and circulatory capacity has been reported, probably caused by the increased circulatory capacity, which facilitates delivery of blood-borne fuels [<xref ref-type="bibr" rid="gsd5.REF.haller.2000.923">Haller 2000</xref>]. </p>
          <p>In eight individuals who underwent a 14-week aerobic conditioning program in which they pedaled a cycloergometer for 30-40 minutes a day, four days a week at an intensity corresponding to 60% to 70% of maximal heart rate, an increase in work capacity, oxygen uptake, cardiac output, citrate synthase activity, and beta-hydroxyacyl coenzyme A dehydrogenase activity was observed, indicating that moderate aerobic exercise improves exercise capacity in individuals with GSDV [<xref ref-type="bibr" rid="gsd5.REF.haller.2006.922">Haller et al 2006</xref>]. </p>
          <p>Nine individuals who underwent an eight-month supervised aerobic exercise training program including five weekly sessions of walking or cycling for no more than 60 minutes, improved their peak power output, peak oxygen uptake, and ventilatory threshold with no evidence of negative outcomes, suggesting that under carefully controlled conditions individuals with GSDV may exercise safely and may respond favorably to training [<xref ref-type="bibr" rid="gsd5.REF.matemuioz.2007.297">Mat&#x000e9;-Mu&#x000f1;oz et al 2007</xref>].</p>
          <p>A systematic review of physical training for GSDV published in the Cochrane Database concluded that there are no randomized or quasi-randomized controlled trials of aerobic training in people with GSDV; however, three studies using small numbers of participants provided some evidence that aerobic training improves fitness without adverse events in people with GSDV. They suggested that it would be safe and worthwhile to conduct larger controlled trials of aerobic training in patients with GSDV [<xref ref-type="bibr" rid="gsd5.REF.quinlivan.2011.CD007931">Quinlivan et al 2011</xref>].</p>
          <p>In a subcohort of 63 patients (out of 239 registered) interviewed for their physical activity habits and whose peak oxygen uptake (and index of peak cardiorespiratory fitness and peak muscle oxidative capacity) were measured, the 32% who were physically active had higher levels of peak oxygen uptake (by 23%, p=0.003) and were more likely to improve their clinical course over a four-year period compared with inactive patients (odds ratio = 225; 95% confidence intervals 20.3 to 2496.7) after controlling for age. Moreover, for 81% of patients in the physically active cohort, clinical disease was reclassified as less severe. Mean peak oxygen uptake was very low, especially in women, where it barely reached the limit (13 mL O2/kg/min or 3.7 metabolic equivalents (METs, with 1MET equaling 3.5 mL O2/kg/min) necessary for independent living. Age also had a negative effect on peak oxygen uptake. However, the peak oxygen uptake in patients who were physically active was 1.5METs higher than in those who were not active. Seven patients (6 physically active) had a peak oxygen uptake of 8 METs, which is the minimum threshold for optimal health. </p>
          <p>Three daily habits recommended by <xref ref-type="bibr" rid="gsd5.REF.haller.2000.923">Haller [2000]</xref> to improve the quality of life:</p>
          <list list-type="bullet">
            <list-item>
              <p>Avoid intense isometric exercise and maximal aerobic exercise, which triggers cramps and, potentially, myoglobinuria (see <xref ref-type="sec" rid="gsd5.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</xref>).</p>
            </list-item>
            <list-item>
              <p>Avoid a totally sedentary life, which induces deconditioning.</p>
            </list-item>
            <list-item>
              <p>Engage in regular, moderate aerobic exercise, which improves cardiorespiratory capacity and increases delivery of blood-borne fuels, a sort of permanent "second wind" (i.e., decrease in heart rate and perceived exertion during exercise) effect [<xref ref-type="bibr" rid="gsd5.REF.ollivier.2005.637">Ollivier et al 2005</xref>].</p>
            </list-item>
          </list>
          <sec id="gsd5.Pharmacologic_and_Nutritional_Treat">
            <title>Pharmacologic and Nutritional Treatments</title>
            <p>Two systematic reviews of pharmacologic and nutritional treatments for GSDV were published in the Cochrane Database [<xref ref-type="bibr" rid="gsd5.REF.quinlivan.2004.CD003458">Quinlivan &#x00026; Beynon 2004</xref>, <xref ref-type="bibr" rid="gsd5.REF.quinlivan.2008.CD003458">Quinlivan et al 2008</xref>]. The authors' conclusions:</p>
            <list list-type="bullet">
              <list-item>
                <p>There is no evidence of significant benefit from any specific nutritional or pharmacologic treatment for GSDV.</p>
              </list-item>
              <list-item>
                <p>Low-dose creatine supplementation demonstrated a statistically significant benefit, albeit modest, in ischemic exercise in a small number of individuals.</p>
              </list-item>
              <list-item>
                <p>Ingestion of oral sucrose immediately prior to exercise reduces perceived ratings of exertion and heart rate and improves exercise tolerance. This treatment does not influence sustained or unexpected exercise.</p>
              </list-item>
              <list-item>
                <p>A carbohydrate-rich diet was of benefit. </p>
              </list-item>
              <list-item>
                <p>Because of the rarity of GSDV, multicenter collaboration and standardized assessment protocols are needed for future treatment trials.</p>
              </list-item>
            </list>
            <p>
              <bold>Pharmacologic treatments</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Creatine monohydrate</bold> in a placebo-controlled crossover trial with nine affected individuals improved symptoms and increased their capacity for ischemic, isometric forearm exercise [<xref ref-type="bibr" rid="gsd5.REF.vorgerd.2000.956">Vorgerd et al 2000</xref>]. This positive effect did not result from increased levels of phosphocreatine in muscle. Rather, creatine may have a quenching effect on the potassium-mediated changes in membrane excitability. A subsequent clinical trial with high doses of creatine monohydrate in 19 individuals lowered exercise intolerance [<xref ref-type="bibr" rid="gsd5.REF.vorgerd.2002.97">Vorgerd et al 2002</xref>]. Thus, the indication for symptomatic therapy with creatine monohydrate needs to be strengthened. </p>
              </list-item>
              <list-item>
                <p><bold>Ramipril,</bold> an ACE inhibitor, used in a randomized, placebo-controlled, double-blind pilot trial in eight persons with GSDV, decreased disability and improved exercise physiology only in those individuals with the <italic toggle="yes">ACE</italic> D/D genotype (see <xref ref-type="sec" rid="gsd5.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>) [<xref ref-type="bibr" rid="gsd5.REF.martinuzzi.2008.350">Martinuzzi et al 2008</xref>].</p>
              </list-item>
            </list>
            <p>
              <bold>Nutritional treatments</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>In a single-blind, randomized, placebo-controlled crossover study in 12 individuals with GSDV, <xref ref-type="bibr" rid="gsd5.REF.vissing.2003b.2503">Vissing &#x00026; Haller [2003b]</xref> found that ingestion of 75 g of sucrose markedly improved exercise tolerance. </p>
              </list-item>
              <list-item>
                <p>Ingesting simple carbohydrates (adult dose: 30-40 g glucose, fructose, or sucrose, or ~440 mL of most commercially available sport drinks; pediatric dose: 20 g) about five minutes before engaging in strenuous exercise such as brisk walking (or physical education classes in the younger individuals) can be helpful [<xref ref-type="bibr" rid="gsd5.REF.perez.2007.880">Perez et al 2007</xref>, <xref ref-type="bibr" rid="gsd5.REF.andersen.2008.786">Andersen et al 2008</xref>]. In addition to increasing exercise capacity and sense of well-being, the treatment may protect against exercise-induced rhabdomyolysis. </p>
              </list-item>
              <list-item>
                <p>Ingestion of sucrose before exercise combined with an aerobic conditioning program is reasonable [<xref ref-type="bibr" rid="gsd5.REF.amato.2003.2481">Amato 2003</xref>]. </p>
              </list-item>
              <list-item>
                <p>Individuals with GSDV can also benefit from adopting a diet rich in complex carbohydrates (i.e., with a high proportion (65%) of complex carbohydrates such as those found in vegetables, fruits, cereals, bread, pasta, and rice) and a low proportion (20%) of fat [<xref ref-type="bibr" rid="gsd5.REF.andersen.2008.1359">Andersen &#x00026; Vissing 2008</xref>].</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="gsd5.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>See <xref ref-type="sec" rid="gsd5.Treatment_of_Manifestations">Treatment of Manifestations</xref> and <xref ref-type="sec" rid="gsd5.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</xref>.</p>
        </sec>
        <sec id="gsd5.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>To prevent muscle breakdown (rhabdomyolysis) and myoglobinuria-induced renal damage: follow the exercise and nutritional measures described in <xref ref-type="sec" rid="gsd5.Treatment_of_Manifestations">Treatment of Manifestations</xref>. </p>
        </sec>
        <sec id="gsd5.Surveillance">
          <title>Surveillance</title>
          <p>Appropriate surveillance includes:</p>
          <list list-type="bullet">
            <list-item>
              <p>Annual routine physical examination</p>
            </list-item>
            <list-item>
              <p>Annual review of diet</p>
            </list-item>
          </list>
        </sec>
        <sec id="gsd5.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Exercises that involve heavy static contractions or induce severe myalgia should be avoided [<xref ref-type="bibr" rid="gsd5.REF.quinlivan.2011.CD007931">Quinlivan et al 2011</xref>, <xref ref-type="bibr" rid="gsd5.REF.lucia.2012.322">Lucia et al 2012</xref>].</p>
          <p>Exercises that should be avoided in patients with GSDV [<xref ref-type="bibr" rid="gsd5.REF.lucia.2008.568">Lucia et al 2008</xref>] are the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Static muscle contractions (e.g., handgrip exercises)</p>
            </list-item>
            <list-item>
              <p>Static muscle contractions or heavy loads on low muscle mass (e.g., weightlifting)</p>
            </list-item>
            <list-item>
              <p>Dynamic exercises at a high-intensity level (e.g., competitive ball games)</p>
            </list-item>
            <list-item>
              <p>Exercises with a high involvement of eccentric (lengthening) muscle contractions (e.g., jumps)</p>
            </list-item>
            <list-item>
              <p>Very intense dynamic aerobic exercise (e.g., running, strenuous swimming, or cycling) except in individuals who are very fit and well habituated </p>
            </list-item>
          </list>
          <p><bold>General anesthetics.</bold> Risk of acute muscle damage is reported with certain general anesthetics (usually muscle relaxants and inhaled anesthetics), although in practice, problems appear to be rare. One report showed hyperthermia, pulmonary edema, and rhabdomyolysis [<xref ref-type="bibr" rid="gsd5.REF.lobato.1999.303">Lobato et al 1999</xref>]; however, GSDV does not appear to cause severe perioperative problems in routine anesthetic care. Nonetheless, measures for preventing muscle ischemia and rhabdomyolysis should be taken in individuals with GSDV [<xref ref-type="bibr" rid="gsd5.REF.bollig.2013.817">Bollig 2013</xref>]. </p>
          <p><bold>Lipid-lowering drugs.</bold> A study in which 136 individuals with myopathy induced by one of the three lipid-lowering drugs atorvastatin, cerivastatin, and simvastatin were tested for the two more frequent <italic toggle="yes">PYGM</italic> pathogenic variants (p.Arg50Ter, p.Gly205Ser) revealed 20-fold more <italic toggle="yes">PYGM</italic> heterozygotes than expected for the general population [<xref ref-type="bibr" rid="gsd5.REF.vladutiu.2006.153">Vladutiu et al 2006</xref>]. These findings provide preliminary evidence that <italic toggle="yes">PYGM</italic> heterozygotes may be predisposed to statin-induced myopathy; however, because only two pathogenic variants were assessed, some individuals in this study who were presumed to be carriers could actually be compound heterozygotes. Thus, clinicians should be cautious when recommending statins to individuals who have GSDV or are carriers for a <italic toggle="yes">PYGM</italic> pathogenic variant.</p>
        </sec>
        <sec id="gsd5.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Early diagnosis of GSDV in relatives at risk may improve long-term outcome by heightening awareness of the need to avoid repetitive episodes of muscle damage that may lead to rhabdomyolysis and fixed weakness. </p>
          <list list-type="bullet">
            <list-item>
              <p>When the family-specific <italic toggle="yes">PYGM</italic> pathogenic variants are known, molecular genetic testing can be used.</p>
            </list-item>
            <list-item>
              <p>When the family-specific <italic toggle="yes">PYGM</italic> pathogenic variants are not known, a reliable and accurate diagnosis of GSDV could be reached following the criteria described in <xref ref-type="sec" rid="gsd5.Diagnosis">Diagnosis</xref>.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="gsd5.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="gsd5.Pregnancy_Management">
          <title>Pregnancy Management </title>
          <p>The condition does not appear to adversely affect pregnancy and childbirth outcomes [<xref ref-type="bibr" rid="gsd5.REF.quinlivan.2010.1182">Quinlivan et al 2010</xref>, <xref ref-type="bibr" rid="gsd5.REF.lucia.2012.322">Lucia et al 2012</xref>].</p>
        </sec>
        <sec id="gsd5.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p><bold>Gene therapy.</bold> An adenoviral recombinant containing the full-length human myophosphorylase cDNA was efficiently transduced into phosphorylase-deficient sheep and human myoblasts, where it restored enzyme activity [<xref ref-type="bibr" rid="gsd5.REF.pari.1999.1352">Pari et al 1999</xref>].</p>
          <p>Adenovirus and adeno-associated virus-mediated delivery of human phosphorylase cDNA and LacZ cDNA to muscle in the ovine (sheep) model of McArdle disease showed expression of functional myophosphorylase and some re-expression of the non-muscle glycogen phosphorylase isoforms (liver and brain isoforms) in regenerating fibers [<xref ref-type="bibr" rid="gsd5.REF.howell.2008.248">Howell et al 2008</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="gsd5.Other">
          <title>Other</title>
          <p><bold>Vitamin B</bold><sub><bold>6</bold></sub> has been used because the overall body stores of pyridoxal phosphate are depleted in GSDV. A beneficial effect has been documented in two individuals, but this requires confirmation [<xref ref-type="bibr" rid="gsd5.REF.phoenix.1998.210">Phoenix et al 1998</xref>, <xref ref-type="bibr" rid="gsd5.REF.sato.2012.436">Sato et al 2012</xref>]. </p>
          <p><bold>Branched-chain amino acids (BCA).</bold> Administration of BCA as alternative fuels to glycogen to six individuals worsened bicycle exercise capacity, possibly because of the free fatty acid-lowering effect of the amino acids [<xref ref-type="bibr" rid="gsd5.REF.maclean.1998.1456">MacLean et al 1998</xref>].</p>
        </sec>
      </sec>
      <sec id="gsd5.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="gsd5.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Glycogen storage disease type V (GSDV) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="gsd5.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">PYGM</italic> pathogenic variant). </p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic. Note: manifesting heterozygotes were reported before genetic testing was available [<xref ref-type="bibr" rid="gsd5.REF.manfredi.1993.91">Manfredi et al 1993</xref>]; such observations could be attributable to lack of identification of the second pathogenic variant. </p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic. Manifesting heterozygotes were reported before the availability of genetic testing [<xref ref-type="bibr" rid="gsd5.REF.manfredi.1993.91">Manfredi et al 1993</xref>]. However, in one study including eight individuals with GSDV, seven heterozygotes, and 11 controls (individuals who are neither affected nor heterozygotes), the heterozygotes had values of exercise capacity indicators (maximal oxidative capacity and peak lactate response) identical to controls, suggesting that they are not prone to developing symptoms of GSDV [<xref ref-type="bibr" rid="gsd5.REF.andersen.2006.716">Andersen et al 2006</xref>].</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with GSDV are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">PYGM</italic>.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="gsd5.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible once the <italic toggle="yes">PYGM</italic> pathogenic variants have been identified in the family.</p>
        </sec>
        <sec id="gsd5.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="gsd5.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="gsd5.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p><bold>Molecular genetic testing.</bold> If the <italic toggle="yes">PYGM</italic> pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing.</p>
          <p><bold>Biochemical testing.</bold> Biochemical testing cannot be done on fetal tissue as myophosphorylase is expressed only in differentiated muscle cells.</p>
          <p>Requests for prenatal testing for conditions such as GSDV are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">PYGM</italic> pathogenic variants have been identified. </p>
        </sec>
      </sec>
      <sec id="gsd5.Resources">
        <title>Resources</title>
      </sec>
      <sec id="gsd5.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="gsd5.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The muscle glycogen phosphorylase (<italic toggle="yes">PYGM</italic>, glycogen phosphorylase, &#x003b1;-1,4-glucan orthophosphate glycosyltransferase, EC 2.4.1.1.) initiates glycogen breakdown by removing &#x003b1;-1,4-glucosyl residues with phosphate ion ('inorganic phosphate') consumption (i.e., phosphorylytically) from the outer branches of glycogen with liberation of glucose-1-phosphate. The enzyme exists as a homodimer containing two identical subunits of 97 kd each. The dimers associate into a tetramer to form the enzymatically active phosphorylase A.</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">PYGM</italic> spans 14 kb containing 20 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="gsd5" object-id="gsd5.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign allelic variants.</bold> Five single-nucleotide benign variants in the coding region have been annotated: three nonsynonymous and two synonymous changes have been identified (see <xref ref-type="table" rid="gsd5.T.pygm_pathogenic_variants_other_th">Table 4</xref>). Ideally, synonymous exonic allelic variants found in symptomatic individuals in whom no other <italic toggle="yes">PYGM</italic> pathogenic variant was identified should be tested for their potential effect on mRNA splicing [<xref ref-type="bibr" rid="gsd5.REF.cartegni.2002.285">Cartegni et al 2002</xref>]. The synonymous mutations at lysine residues 205 and 609 were found to severely alter <italic toggle="yes">PYGM</italic> transcripts in symptomatic individuals [<xref ref-type="bibr" rid="gsd5.REF.fernandezcadenas.2003.1432">Fernandez-Cadenas et al 2003</xref>, <xref ref-type="bibr" rid="gsd5.REF.garciaconsuegra.2009.198">Garc&#x000ed;a-Consuegra et al 2009</xref>].</p>
          <p><bold>Pathogenic allelic variants.</bold> To date, more than 140 pathogenic variants causing PYGM deficiency have been identified. See <xref ref-type="table" rid="gsd5.T.classes_of_mutations_observed_in_">Table 2</xref> for classes of mutations observed [<xref ref-type="bibr" rid="gsd5.REF.andreu.2007.53">Andreu et al 2007</xref>; HGMD, accessed June 2, 2014].</p>
          <p>Note that the synonymous mutation c.1827G&#x0003e;A at lysine residue 609 was found to severely alter <italic toggle="yes">PYGM</italic> transcripts [<xref ref-type="bibr" rid="gsd5.REF.fernandezcadenas.2003.1432">Fernandez-Cadenas et al 2003</xref>] (see <xref ref-type="table" rid="gsd5.T.selected_pygm_allelic_variants">Table 3</xref>). Another synonymous variant, c.645G&#x0003e;A at lysine amino acid 215, is also predicted to be pathogenic by affecting <italic toggle="yes">PYGM</italic> transcription [<xref ref-type="bibr" rid="gsd5.REF.garciaconsuegra.2009.198">Garc&#x000ed;a-Consuegra et al 2009</xref>].</p>
          <table-wrap id="gsd5.T.classes_of_mutations_observed_in_" position="anchor" orientation="portrait">
            <label>Table 2.</label>
            <caption>
              <p>Classes of Mutations Observed in <italic toggle="yes">PYGM</italic></p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Genetic Mechanism</th>
                  <th id="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Number of Mutations</th>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Nucleotide substitutions (missense/nonsense)</td>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">86</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Nucleotide substitutions (splicing)</td>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">14</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Small deletions</td>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">20</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Small insertions (including duplications)</td>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">5</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Small indel mutations&#x000a0;<sup>1</sup></td>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">3</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Gross deletions</td>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">4</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">
                    <bold>Total</bold>
                  </td>
                  <td headers="hd_b_gsd5.T.classes_of_mutations_observed_in__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">
                    <bold>144</bold>
                  </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gsd5.TF.2">
                <p>From <xref ref-type="bibr" rid="gsd5.REF.bruno.2006.718">Bruno et al [2006]</xref>, <xref ref-type="bibr" rid="gsd5.REF.andreu.2007.53">Andreu et al [2007]</xref>, <xref ref-type="bibr" rid="gsd5.REF.aquaron.2007.235">Aquaron et al [2007]</xref>, <xref ref-type="bibr" rid="gsd5.REF.deschauer.2007.797">Deschauer et al [2007]</xref>, <xref ref-type="bibr" rid="gsd5.REF.rubio.2007a.203">Rubio et al [2007a]</xref>, <xref ref-type="bibr" rid="gsd5.REF.lucia.2012.322">Lucia et al [2012]</xref>, and The Human Gene Mutation Database (HGMD)</p>
              </fn>
              <fn id="gsd5.TF.2.1">
                <p>1. Indel mutations (also called "indels") are the simultaneous insertion and deletion of nucleotide sequence(s) at the same site in a gene.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <table-wrap id="gsd5.T.selected_pygm_allelic_variants" position="anchor" orientation="portrait">
            <label>Table 3.</label>
            <caption>
              <p>Selected <italic toggle="yes">PYGM</italic> Allelic Variants</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Variant <break/>Classification</th>
                  <th id="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Protein Amino Acid Change&#x000a0;<sup>1</sup><break/>(Alias&#x000a0;<sup>2</sup>)</th>
                  <th id="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_1" align="left" valign="middle" rowspan="5" colspan="1">
                    <bold>Benign</bold>
                  </td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.564C&#x0003e;A</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Asn188Lys</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="13" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&#x00026;id=164663907">NM_005609.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&#x00026;id=5032009">NP_005600.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.1240C&#x0003e;G</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Arg414Gly</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.1289C&#x0003e;T</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Ser430Leu</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.1365C&#x0003e;T</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.=</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.1494C&#x0003e;T</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.=</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_1" align="left" valign="middle" rowspan="8" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.148C&#x0003e;T</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Arg50Ter<break/>(Arg49*) </td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.255C&#x0003e;A</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Tyr85Ter<break/>(Tyr84*) </td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.613G&#x0003e;A</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Gly205Ser<break/>(Gly204Ser) </td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="top" rowspan="1" colspan="1">c.645G&#x0003e;A </td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="top" rowspan="1" colspan="1">p.=<break/>(Lys215Lys) </td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.1628A&#x0003e;C</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Lys543Thr<break/>(Lys542Thr) </td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.1827G&#x0003e;A</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.=<break/>(Lys608Lys) </td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.2128_2130delTTC</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Phe710del<break/>(708/709del) </td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.2392T&#x0003e;C</td>
                  <td headers="hd_b_gsd5.T.selected_pygm_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Trp798Arg<break/>(Trp797Arg) </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gsd5.TF.3">
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants. </p>
              </fn>
              <fn id="gsd5.TF.3.1">
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature. </p>
              </fn>
              <fn id="gsd5.TF.3.2">
                <p>1. p.= indicates that no amino acid change is expected. </p>
              </fn>
              <fn id="gsd5.TF.3.3">
                <p>2. Variant designation that does not conform to current naming conventions. For <italic toggle="yes">PYGM</italic>, the alias for a pathogenic protein amino acid change was in the past one residue less, as it follows a convention of designating the second amino acid (Ser) as residue number one, rather than the standard of using the initiating Met residue as number one.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Recurrent pathogenic variants (<xref ref-type="table" rid="gsd5.T.pygm_pathogenic_variants_other_th">Table 4</xref>) include the following: </p>
          <list list-type="bullet">
            <list-item>
              <p>p.Arg50Ter is a so-called "common" pathogenic variant in exon 1 of <italic toggle="yes">PYGM</italic> that results in a premature stop codon. This pathogenic variant was identified in approximately 32%-71% of all mutant alleles [<xref ref-type="bibr" rid="gsd5.REF.andreu.1998.260">Andreu et al 1998</xref>, <xref ref-type="bibr" rid="gsd5.REF.martin.2001.574">Mart&#x000ed;n et al 2001</xref>, <xref ref-type="bibr" rid="gsd5.REF.bruno.2006.718">Bruno et al 2006</xref>, <xref ref-type="bibr" rid="gsd5.REF.aquaron.2007.235">Aquaron et al 2007</xref>, <xref ref-type="bibr" rid="gsd5.REF.deschauer.2007.797">Deschauer et al 2007</xref>, <xref ref-type="bibr" rid="gsd5.REF.rubio.2007a.203">Rubio et al 2007a</xref>, <xref ref-type="bibr" rid="gsd5.REF.vieitez.2011.817">Vieitez et al 2011</xref>, <xref ref-type="bibr" rid="gsd5.REF.lucia.2012.322">Lucia et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>p.Gly205Ser is the second most frequent pathogenic variant in various European and US populations, representing approximately 9% of mutant alleles.</p>
            </list-item>
            <list-item>
              <p>In an analysis of 239 individuals of Spanish origin, the private mutation p.Trp798Arg accounted for 12% of mutant alleles [<xref ref-type="bibr" rid="gsd5.REF.lucia.2012.322">Lucia et al 2012</xref>]</p>
            </list-item>
          </list>
          <table-wrap id="gsd5.T.pygm_pathogenic_variants_other_th" position="anchor" orientation="portrait">
            <label>Table 4.</label>
            <caption>
              <p><italic toggle="yes">PYGM</italic> Pathogenic Variants Other than p.Arg50Ter and p.Gly205Ser with Relatively High Frequency in Specific Populations</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Population</th>
                  <th id="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Pathogenic Variant</th>
                  <th id="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Frequency</th>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Japanese&#x000a0;<sup>1</sup></td>
                  <td headers="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1"><xref ref-type="table" rid="gsd5.T.selected_pygm_allelic_variants">p.Phe710del</xref>
</td>
                  <td headers="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">64%</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Spanish&#x000a0;<sup>2</sup></td>
                  <td headers="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1"><xref ref-type="table" rid="gsd5.T.selected_pygm_allelic_variants">p.Trp798Arg</xref>
</td>
                  <td headers="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">12%</td>
                </tr>
                <tr>
                  <td headers="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Central European&#x000a0;<sup>3</sup></td>
                  <td headers="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1"><xref ref-type="table" rid="gsd5.T.selected_pygm_allelic_variants">p.Tyr85Ter</xref>
</td>
                  <td headers="hd_b_gsd5.T.pygm_pathogenic_variants_other_th_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">25%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gsd5.TF.4">
                <label>1.</label>
                <p>
                  <xref ref-type="bibr" rid="gsd5.REF.tsujino.1994.44">Tsujino et al [1994]</xref>
                </p>
              </fn>
              <fn id="gsd5.TF.4.1">
                <label>2.</label>
                <p><xref ref-type="bibr" rid="gsd5.REF.martin.2001.574">Mart&#x000ed;n et al [2001]</xref>, <xref ref-type="bibr" rid="gsd5.REF.rubio.2007a.203">Rubio et al [2007a]</xref>; <xref ref-type="bibr" rid="gsd5.REF.lucia.2012.322">Lucia et al [2012]</xref></p>
              </fn>
              <fn id="gsd5.TF.4.2">
                <label>3.</label>
                <p><xref ref-type="bibr" rid="gsd5.REF.deschauer.2003.105">Deschauer et al [2003]</xref>, <xref ref-type="bibr" rid="gsd5.REF.martin.2004.17">Mart&#x000ed;n et al [2004]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The size of monomeric <italic toggle="yes">PYGM</italic> is 841 amino acids in human skeletal muscle. PYGM protein has a molecular weight of 97 kd.</p>
          <p><bold>Abnormal gene product.</bold> Pathogenic variants in <italic toggle="yes">PYGM</italic> reduce or abolish myophosphorylase enzyme activity in muscle [<xref ref-type="bibr" rid="gsd5.REF.dimauro.2002.189">Dimauro et al 2002</xref>]. Missense mutations may affect contact dimer pairs, which are involved in the propagation of allosteric effects of this regulatory protein. Mutations can also disrupt hydrogen bond interactions and affect substrate or effector-/inhibitor-binding sites. Mutations yielding premature stop codons (PTC) predict truncated proteins but may also produce deep effects at the transcriptional level (i.e., nonsense-mediated decay (NMD), disruption of splicing machinery yielding aberrant transcript) [<xref ref-type="bibr" rid="gsd5.REF.martin.2001.574">Mart&#x000ed;n et al 2001</xref>, <xref ref-type="bibr" rid="gsd5.REF.fernandezcadenas.2003.1432">Fernandez-Cadenas et al 2003</xref>, Garcia-Consuegra 2009]. It should be noted that 35% of all pathogenic variants in <italic toggle="yes">PYGM</italic> result in PTC. One study in 28 individuals harboring 17 different pathogenic variants with PTCs showed that the NMD mechanism occurred in 92% and that the common pathogenic variant p.Arg50Ter elicited decay in all genotypes tested [<xref ref-type="bibr" rid="gsd5.REF.nogalesgadea.2008.277">Nogales-Gadea et al 2008</xref>]. </p>
          <p>A knock-in mouse model for the common variant p.Arg50Ter has been shown to recapitulate most of the signs and symptoms of GSDV, and consequently could be of great value for in-depth studies of molecular pathogenesis and for exploring new therapeutic approaches for genetic disorders caused by premature stop codons [<xref ref-type="bibr" rid="gsd5.REF.nogalesgadea.2012.2048">Nogales-Gadea et al 2012</xref>].</p>
        </sec>
      </sec>
      <sec id="gsd5.References">
        <title>References</title>
        <sec id="gsd5.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="gsd5.Literature_Cited.reflist0">
            <ref id="gsd5.REF.amato.2003.2481">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Amato</surname>
                    <given-names>AA</given-names>
                  </name>
                </person-group>
                <article-title>Sweet success--a treatment for McArdle's disease.</article-title>
                <source>N Engl J Med</source>
                <year>2003</year>
                <volume>349</volume>
                <fpage>2481</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">14695407</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.andersen.2006.716">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dun&#x000f8;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Do carriers of PYGM mutations have symptoms of McArdle disease?</article-title>
                <source>Neurology</source>
                <year>2006</year>
                <volume>67</volume>
                <fpage>716</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16924035</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.andersen.2008.786">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Effect of oral sucrose shortly before exercise on work capacity in McArdle disease.</article-title>
                <source>Arch Neurol</source>
                <year>2008</year>
                <volume>65</volume>
                <fpage>786</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18541798</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.andersen.2008.1359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <year>2008</year>
                <volume>79</volume>
                <fpage>1359</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">19010947</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.andreu.1998.260">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gamez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cervera</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navarro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arbos</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamburino</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Molecular genetic analysis of McArdle's disease in Spanish patients.</article-title>
                <source>Neurology</source>
                <year>1998</year>
                <volume>51</volume>
                <fpage>260</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">9674815</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.andreu.2007.53">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nogales-Gadea</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassandrini</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>McArdle disease: molecular genetic update.</article-title>
                <source>Acta Myol</source>
                <year>2007</year>
                <volume>26</volume>
                <fpage>53</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17915571</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.aquaron.2007.235">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aquaron</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berg&#x000e9;-Lefranc</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellissier</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montfort</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figarella-Branger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coquet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratrice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouget</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Molecular characterization of myophosphorylase deficiency (McArdle disease) in 34 patients from Southern France: identification of 10 new mutations. Absence of genotype-phenotype correlation.</article-title>
                <source>Neuromuscul Disord</source>
                <year>2007</year>
                <volume>17</volume>
                <fpage>235</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">17324573</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.bartram.1993.1291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bartram</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clague</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beynon</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases.</article-title>
                <source>Hum Mol Genet</source>
                <year>1993</year>
                <volume>2</volume>
                <fpage>1291</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">8401511</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.bollig.2013.817">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bollig</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>McArdle's disease (glycogen storage disease type V) and anesthesia--a case report and review of the literature.</article-title>
                <source>Paediatr Anaesth</source>
                <year>2013</year>
                <volume>23</volume>
                <fpage>817</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">23565573</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.bruno.2000.137">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>HyperCKemia as the only sign of McArdle's disease in a child.</article-title>
                <source>J Child Neurol</source>
                <year>2000</year>
                <volume>15</volume>
                <fpage>137</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10695902</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.bruno.2006.718">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassandrini</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinuzzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toscano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moggio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morandi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Servidei</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mongini</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Musumeci</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamperti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filosto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>McArdle disease: the mutation spectrum of PYGM in a large Italian cohort.</article-title>
                <source>Hum Mutat</source>
                <year>2006</year>
                <volume>27</volume>
                <fpage>718</fpage>
                <pub-id pub-id-type="pmid">16786513</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.buckley.2014.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buckley</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinlivan</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sim</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eston</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Short</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <article-title>Heart rate and perceived muscle pain responses to a functional walking test in McArdle disease.</article-title>
                <source>J Sports Sci.</source>
                <year>2014</year>
                <fpage>1</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">24731154</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.cartegni.2002.285">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cartegni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chew</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krainer</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <article-title>Listening to silence and understanding nonsense: exonic mutations that affect splicing.</article-title>
                <source>Nat Rev Genet</source>
                <year>2002</year>
                <volume>3</volume>
                <fpage>285</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">11967553</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.deschauer.2003.105">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Deschauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hertel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zierz</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Two novel mutations in the myophosphorylase gene in a patient with McArdle disease.</article-title>
                <source>Muscle Nerve</source>
                <year>2003</year>
                <volume>27</volume>
                <fpage>105</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12508303</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.deschauer.2007.797">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Deschauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgenroth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joshi</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gl&#x000e4;ser</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aasly</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schreiber</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knape</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zierz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Analysis of spectrum and frequencies of mutations in McArdle disease. Identification of 13 novel mutations.</article-title>
                <source>J Neurol</source>
                <year>2007</year>
                <volume>254</volume>
                <fpage>797</fpage>
                <lpage>802</lpage>
                <pub-id pub-id-type="pmid">17404776</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.dimauro.2002.189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dimauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadjigeorgiou</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <article-title>Myophosphorylase deficiency (glycogenosis type V; McArdle disease).</article-title>
                <source>Curr Mol Med</source>
                <year>2002</year>
                <volume>2</volume>
                <fpage>189</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">11949935</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.elschahawi.1997.81">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>el-Schahawi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsujino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarrazin</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LeRoux</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Sudden infant death syndrome (SIDS) in a family with myophosphorylase deficiency.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1997</year>
                <volume>7</volume>
                <fpage>81</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">9131647</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.elschahawi.1996.579">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>el-Schahawi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsujino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Diagnosis of McArdle's disease by molecular genetic analysis of blood.</article-title>
                <source>Neurology</source>
                <year>1996</year>
                <volume>47</volume>
                <fpage>579</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">8757044</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.fernandezcadenas.2003.1432">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fernandez-Cadenas</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gamez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Splicing mosaic of the myophosphorylase gene due to a silent mutation in McArdle disease.</article-title>
                <source>Neurology</source>
                <year>2003</year>
                <volume>61</volume>
                <fpage>1432</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">14638972</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.garciaconsuegra.2009.198">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Consuegra</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nogales-Gadea</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bautista</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jim&#x000e9;nez</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luc&#x000ed;a</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Novel mutations in patients with McArdle disease by analysis of skeletal muscle mRNA.</article-title>
                <source>J Med Genet</source>
                <year>2009</year>
                <volume>46</volume>
                <fpage>198</fpage>
                <lpage>202</lpage>
                <pub-id pub-id-type="pmid">19251976</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.gomezgallego.2008.134">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Gallego</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santiago</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mor&#x000e1;n</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mat&#x000e9;-Mu&#x000f1;oz</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>del Valle</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Consuegra</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foster</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucia</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>The I allele of the ACE gene is associated with improved exercise capacity in women with McArdle disease.</article-title>
                <source>Br J Sports Med</source>
                <year>2008</year>
                <volume>42</volume>
                <fpage>134</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">17616548</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.gospe.1998.1228">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gospe</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>El-Schahawi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoye</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorin</surname>
                    <given-names>FA</given-names>
                  </name>
                </person-group>
                <article-title>Asymptomatic McArdle's disease associated with hyper-creatine kinase-emia and absence of myophosphorylase.</article-title>
                <source>Neurology</source>
                <year>1998</year>
                <volume>51</volume>
                <fpage>1228</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9781574</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.haller.2000.923">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>Treatment of McArdle disease.</article-title>
                <source>Arch Neurol</source>
                <year>2000</year>
                <volume>57</volume>
                <fpage>923</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10891971</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.haller.2002.1395">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Spontaneous "second wind" and glucose-induced second "second wind" in McArdle disease: oxidative mechanisms.</article-title>
                <source>Arch Neurol</source>
                <year>2002</year>
                <volume>59</volume>
                <fpage>1395</fpage>
                <lpage>402</lpage>
                <pub-id pub-id-type="pmid">12223025</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.haller.2006.922">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wyrick</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taivassalo</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Aerobic conditioning: an effective therapy in McArdle's disease.</article-title>
                <source>Ann Neurol</source>
                <year>2006</year>
                <volume>59</volume>
                <fpage>922</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16718692</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.howell.2008.248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Howell</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunton</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Everaardt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karpati</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle's disease: expression and re-expression of glycogen phosphorylase.</article-title>
                <source>Neuromuscul Disord</source>
                <year>2008</year>
                <volume>18</volume>
                <fpage>248</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">18343113</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.ito.2003.438">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saito</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shishikura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukuda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugie</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osawa</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>A 1-year-old infant with McArdle disease associated with hyper-creatine kinase-emia during febrile episodes.</article-title>
                <source>Brain Dev</source>
                <year>2003</year>
                <volume>25</volume>
                <fpage>438</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">12907279</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.kazemiesfarjani.2002.153">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kazemi-Esfarjani</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skomorowska</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>A nonischemic forearm exercise test for McArdle disease.</article-title>
                <source>Ann Neurol</source>
                <year>2002</year>
                <volume>52</volume>
                <fpage>153</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12210784</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.kubisch.1998.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kubisch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wicklein</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jentsch</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <article-title>Molecular diagnosis of McArdle disease: revised genomic structure of the myophosphorylase gene and identification of a novel mutation.</article-title>
                <source>Hum Mutat</source>
                <year>1998</year>
                <volume>12</volume>
                <fpage>27</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">9633816</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.lobato.1999.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lobato</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janelle</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urdaneta</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malias</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease.</article-title>
                <source>Anesthesiology</source>
                <year>1999</year>
                <volume>91</volume>
                <fpage>303</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10422956</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.lucia.2008.568">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lucia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nogales-Gadea</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>McArdle disease: what do neurologists need to know?</article-title>
                <source>Nat Clin Pract Neurol</source>
                <year>2008</year>
                <volume>4</volume>
                <fpage>568</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">18833216</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.lucia.2012.322">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lucia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santalla</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nogales-Gadea</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Consuegra</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teijeira</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vieitez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navarro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                </person-group>
                <article-title>Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry.</article-title>
                <source>J Neurol Neurosurg Psychiatr</source>
                <year>2012</year>
                <volume>83</volume>
                <fpage>322</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22250184</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.maclean.1998.1456">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacLean</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>Oral branched-chain amino acids do not improve exercise capacity in McArdle disease.</article-title>
                <source>Neurology</source>
                <year>1998</year>
                <volume>51</volume>
                <fpage>1456</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9818881</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.manfredi.1993.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Manfredi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvestri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serveidei</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricci</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirabella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papacci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rana</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonali</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Manifesting heterozygotes in McArdle's disease: morphological and biochemical studies in a family.</article-title>
                <source>J Neurol Sci</source>
                <year>1993</year>
                <volume>115</volume>
                <fpage>91</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">8468596</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.martin.2001.574">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchbinder</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fern&#x000e1;ndez-Hojas</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>del Hoyo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teijeira</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e1;mez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navarro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fern&#x000e1;ndez</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campos</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cervera</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Culebras</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletterick</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): a genotype-phenotype correlation study.</article-title>
                <source>Ann Neurol</source>
                <year>2001</year>
                <volume>50</volume>
                <fpage>574</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">11706962</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.martin.2004.17">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steenbergen</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Diggelen</surname>
                    <given-names>OP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Visser</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Die-Smulders</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bl&#x000e1;zquez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Molecular analysis of myophosphorylase deficiency in Dutch patients with McArdle's disease.</article-title>
                <source>Ann Hum Genet</source>
                <year>2004</year>
                <volume>68</volume>
                <fpage>17</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">14748827</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.martinuzzi.2008.350">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martinuzzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liava</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trevisi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frare</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonon</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malucelli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manners</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemp</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbiroli</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lodi</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease.</article-title>
                <source>Muscle Nerve</source>
                <year>2008</year>
                <volume>37</volume>
                <fpage>350</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18098237</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.martinuzzi.2003.497">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martinuzzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sartori</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fanin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nascimbeni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valente</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siciliano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mongini</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomelleri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toscano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bindoff</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertelli</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Phenotype modulators in myophosphorylase deficiency.</article-title>
                <source>Ann Neurol</source>
                <year>2003</year>
                <volume>53</volume>
                <fpage>497</fpage>
                <lpage>502</lpage>
                <pub-id pub-id-type="pmid">12666117</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.matemuioz.2007.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mat&#x000e9;-Mu&#x000f1;oz</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chamorro-Vi&#x000f1;a</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Gallego</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santiago</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chicharro</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foster</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nogales-Gadea</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucia</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Favorable responses to acute and chronic exercise in McArdle patients.</article-title>
                <source>Clin J Sport Med</source>
                <year>2007</year>
                <volume>17</volume>
                <fpage>297</fpage>
                <lpage>303</lpage>
                <pub-id pub-id-type="pmid">17620784</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.moustafa.2013.769">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moustafa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patton</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connelly</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <article-title>Unforeseen cardiac involvement in McArdle's disease.</article-title>
                <source>Heart Lung Circ.</source>
                <year>2013</year>
                <volume>22</volume>
                <fpage>769</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">23337261</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.nogalesgadea.2008.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nogales-Gadea</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez-Cadenas</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Consuegra</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Arumi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Expression of the muscle glycogen phosphorylase gene in patients with McArdle disease: the role of nonsense-mediated mRNA decay.</article-title>
                <source>Hum Mutat</source>
                <year>2008</year>
                <volume>29</volume>
                <fpage>277</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">17994553</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.nogalesgadea.2012.2048">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nogales-Gadea</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pin&#x000f3;s</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brull</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Luna</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Arum&#x000ed;</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                </person-group>
                <article-title>Knock-in mice for the R50X mutation in the PYGM gene present with McArdle disease.</article-title>
                <source>Brain</source>
                <year>2012</year>
                <volume>135</volume>
                <fpage>2048</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">22730558</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.ollivier.2005.637">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ollivier</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hogrel</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez-Merino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lafor&#x000ea;t</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Portero</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Exercise tolerance and daily life in McArdle's disease.</article-title>
                <source>Muscle Nerve</source>
                <year>2005</year>
                <volume>31</volume>
                <fpage>637</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">15614801</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.pari.1999.1352">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crerar</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nalbantoglu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoubridge</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsujino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howell</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karpati</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Myophosphorylase gene transfer in McArdle's disease myoblasts in vitro.</article-title>
                <source>Neurology</source>
                <year>1999</year>
                <volume>53</volume>
                <fpage>1352</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10522901</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.perez.2007.880">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mat&#x000e9;-Mu&#x000f1;oz</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foster</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucia</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Exercise capacity in a child with McArdle disease.</article-title>
                <source>J Child Neurol</source>
                <year>2007</year>
                <volume>22</volume>
                <fpage>880</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">17715283</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.phoenix.1998.210">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Phoenix</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkins</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartram</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beynon</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinlivan</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <article-title>Effect of vitamin B6 supplementation in McArdle's disease: a strategic case study.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1998</year>
                <volume>8</volume>
                <fpage>210</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">9631404</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.quinlivan.2010.1182">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quinlivan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Twist</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duno</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassandrini</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rose</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C.</given-names>
                  </name>
                </person-group>
                <article-title>McArdle disease: a clinical review.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>2010</year>
                <volume>81</volume>
                <fpage>1182</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20861058</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.quinlivan.2011.CD007931">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quinlivan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilton-Jones</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckley</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Physical training for McArdle disease.</article-title>
                <source>Cochrane Database Syst Rev.</source>
                <year>2011</year>
                <issue>12</issue>
                <fpage>CD007931</fpage>
                <pub-id pub-id-type="pmid">22161416</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.quinlivan.2004.CD003458">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quinlivan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beynon</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Pharmacological and nutritional treatment for McArdle's disease (Glycogen Storage Disease type V).</article-title>
                <source>Cochrane Database Syst Rev</source>
                <year>2004</year>
                <fpage>CD003458</fpage>
                <pub-id pub-id-type="pmid">15266486</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.quinlivan.2008.CD003458">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quinlivan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beynon</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinuzzi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).</article-title>
                <source>Cochrane Database Syst Rev</source>
                <year>2008</year>
                <fpage>CD003458</fpage>
                <pub-id pub-id-type="pmid">18425888</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.roubertie.1998.269">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roubertie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patte</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pages</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maire</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Echenne</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>McArdle's disease in childhood: report of a new case.</article-title>
                <source>Eur J Paediatr Neurol</source>
                <year>1998</year>
                <volume>2</volume>
                <fpage>269</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">10726830</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.rubio.2007a.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Consuegra</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nogales-Gadea</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blazquez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>A proposed molecular diagnostic flowchart for myophosphorylase deficiency (McArdle disease) in blood samples from Spanish patients.</article-title>
                <source>Hum Mutat</source>
                <year>2007a</year>
                <volume>28</volume>
                <fpage>203</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17221871</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.rubio.2007b.217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Gallego</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santiago</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Consuegra</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barriopedro</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreu</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucia</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Genotype modulators of clinical severity in McArdle disease.</article-title>
                <source>Neurosci Lett</source>
                <year>2007b</year>
                <volume>422</volume>
                <fpage>217</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">17630210</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.sato.2012.436">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugie</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy</article-title>
                <source>Muscle Nerve</source>
                <year>2012</year>
                <volume>45</volume>
                <fpage>436</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">22334182</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.sidhu.2005.U1614">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sidhu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>McArdle's disease (myophosphorylase deficiency) presenting as acute renal failure.</article-title>
                <source>N Z Med J</source>
                <year>2005</year>
                <volume>118</volume>
                <fpage>U1614</fpage>
                <pub-id pub-id-type="pmid">16132075</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.tsujino.1993.241">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsujino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease).</article-title>
                <source>N Engl J Med</source>
                <year>1993</year>
                <volume>329</volume>
                <fpage>241</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">8316268</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.tsujino.1994.44">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsujino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonaka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendell</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenichel</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Three new mutations in patients with myophosphorylase deficiency (McArdle disease).</article-title>
                <source>Am J Hum Genet</source>
                <year>1994</year>
                <volume>54</volume>
                <fpage>44</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">8279469</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.vissing.2003a.539">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>A diagnostic cycle test for McArdle's disease.</article-title>
                <source>Ann Neurol</source>
                <year>2003a</year>
                <volume>54</volume>
                <fpage>539</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">14520671</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.vissing.2003b.2503">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>The effect of oral sucrose on exercise tolerance in patients with McArdle's disease.</article-title>
                <source>N Engl J Med</source>
                <year>2003b</year>
                <volume>349</volume>
                <fpage>2503</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14695410</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.vieitez.2011.817">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vieitez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teijeira</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>San Millan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miranda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ortolano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Louis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laforet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navarro</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Molecular and clinical study of McArdle's disease in a cohort of 123 European patients. Identification of 20 novel mutations.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2011</year>
                <volume>21</volume>
                <fpage>817</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">21802952</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.vladutiu.2006.153">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vladutiu</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simmons</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isackson</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarnopolsky</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peltier</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barboi</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sripathi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <article-title>Genetic risk factors associated with lipid-lowering drug-induced myopathies.</article-title>
                <source>Muscle Nerve</source>
                <year>2006</year>
                <volume>34</volume>
                <fpage>153</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">16671104</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.voduc.2004.163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Voduc</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Arsigny</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McBride</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Donnell</surname>
                    <given-names>DE</given-names>
                  </name>
                </person-group>
                <article-title>McArdle's disease presenting as unexplained dyspnea in a young woman.</article-title>
                <source>Can Respir J</source>
                <year>2004</year>
                <volume>11</volume>
                <fpage>163</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15045049</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.vorgerd.2000.956">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grehl</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jager</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freitag</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patzold</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruns</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fabian</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tegenthoff</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortier</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luttmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zange</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malin</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <article-title>Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial.</article-title>
                <source>Arch Neurol</source>
                <year>2000</year>
                <volume>57</volume>
                <fpage>956</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">10891977</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.vorgerd.2002.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zange</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kley</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grehl</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000fc;sing</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000e4;ger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schr&#x000f6;der</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortier</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fabian</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malin</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luttmann</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study.</article-title>
                <source>Arch Neurol</source>
                <year>2002</year>
                <volume>59</volume>
                <fpage>97</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">11790236</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.walker.2003.640">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tschetter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flanigan</surname>
                    <given-names>KM</given-names>
                  </name>
                </person-group>
                <article-title>McArdle's disease presenting as recurrent cryptogenic renal failure due to occult seizures.</article-title>
                <source>Muscle Nerve</source>
                <year>2003</year>
                <volume>28</volume>
                <fpage>640</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">14571470</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.witting.2014.88">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Witting</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duno</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piraud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Severe axial myopathy in McArdle disease.</article-title>
                <source>JAMA Neurol</source>
                <year>2014</year>
                <volume>71</volume>
                <fpage>88</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">24216972</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd5.REF.wolfe.2000.641">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>GI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burns</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barohn</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>McArdle's disease presenting with asymmetric, late-onset arm weakness.</article-title>
                <source>Muscle Nerve</source>
                <year>2000</year>
                <volume>23</volume>
                <fpage>641</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10716777</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="gsd5.Suggested_Reading">
          <title>Suggested Reading </title>
          <ref-list id="gsd5.Suggested_Reading.reflist0">
            <ref id="gsd5.REF.rommel.2006.295">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rommel</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kley</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dekomien</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epplen</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasenbring</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Muscle pain in myophosphorylase deficiency (McArdle's disease): the role of gender, genotype, and pain-related coping.</article-title>
                <source>Pain</source>
                <year>2006</year>
                <volume>124</volume>
                <fpage>295</fpage>
                <lpage>304</lpage>
                <pub-id pub-id-type="pmid">16793208</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="gsd5.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="gsd5.Acknowledgments">
          <title>Acknowledgments</title>
          <p>Supported by grants from the Fondo de Investigaci&#x000f3;n Sanitaria (FIS PI12/00914, PI10/00036, European Union, Executive Agency for Health and Consumers (EUROMAC) no. 318081, and from Centro de Investigaci&#x000f3;n Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Spain.</p>
        </sec>
        <sec id="gsd5.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>26 June 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>12 May 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>8 May 2006 (cd) Revision: sequence analysis of <italic toggle="yes">PYGM</italic> clinically available</p>
            </list-item>
            <list-item>
              <p>19 April 2006 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>26 August 2005 (ja) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
